




|                  |                       |   |
|------------------|-----------------------|---|
| Name             | Ja Min Byun           |  |
| Current Position | Assistant Professor   |   |
| Country          | Korea                 |   |
| Major Field      | Lymphoid malignancies |   |

## Educational Background

|           |   |
|-----------|---|
| 2004-2010 | Kyung Hee University College of Medicine, Seoul, Korea        |
| 2013-2015 | Master's degree, Kyung Hee University, Seoul, Korea           |
| 2015-2019 | Doctor of Philosophy, Seoul National University, Seoul, Korea |

## Professional Experience

2010.3 - 2011.2  
Internship in Kyung Hee University Hospital, Seoul, Korea

2011.3 - 2015.2  
Residency in the Department of Internal Medicine, Kyung Hee University Hospital , Seoul, Korea

2015.3 - 2017.2  
Clinical fellowship in the Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

2017.3 - 2019.5  
Clinical assistant professor in the Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea

Jun. 2019 - Present  
Assistant professor in the Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

## Other Experience and Professional Memberships

American Society of Hematology / International Member  
European Hematology Association / Junior Member



---

---

## Main Scientific Publications

---

1. **Byun JM**, Min C-K, Kim K et al. Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease. *J Hematol Oncol.* 2022 Oct 23;15(1):150.
  2. **Byun JM**, Kim SA, Koh Y et al. Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. *Curr Probl Cancer.* 2022 Feb;46(1): 100786
  3. Park S, Shin DY, Hong J, Kim I, Koh Y, **Byun JM**, Yoon SS. Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma. *Ther Adv Hematol.* 2021 May 7;12: 20406207211012985
-